FHTXFoghorn Therapeutics Inc.

7.070USD+0.14%Mkt Cap: 419.85M $P/E:

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the Uni…

Key Statistics

Company
Market Cap419.85M $
Enterprise Value291.81M $
Revenue (TTM)36.74M $
Gross Profit-42.09M $
Net Income (TTM)-74.28M $
Revenue/Share0.5520 USD
Last Price7.070 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees106
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN
Valuation
P/E (Trailing)
P/E (Forward)-6.81
PEG
EV/EBITDA-4.40
EV/Revenue7.94
P/S11.33
P/B-5.08
EPS (TTM)-0.98
EPS (Forward)-1.03
52W Range
3.27093% of range7.348
52W High7.348 USD
52W Low3.270 USD
Profitability
Gross Margin-114.57%
Oper. Margin-54.78%
EBITDA Margin-180.61%
Profit Margin-240.33%
ROE68.46%
ROA-37.50%
Growth
Revenue Growth112.70%
Earnings Growth
Cash Flow & Leverage
Operating CF-86.10M $
CapEx (TTM)50.00K $
FCF Margin-141.42%
FCF Yield-12.37%
Net Debt-124.48M $
Net Debt/EBITDA1.88
Balance Sheet
Debt/Equity-0.38
Current Ratio3.36
Quick Ratio3.31
Book Value/Sh-1.3800 USD
Cash/Share2.822 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)11.44 USD
Upside (mean)+61.9%
Target Range9.000 USD14.00 USD
$9.000+61.9% to mean$14.00
# Analysts9
Ownership
Shares Out.59.39M
Float28.08M
Insiders14.13%
Institutions76.70%
Short Interest
Short Ratio4.7d
Short % Float4.91%
Short % Out.2.70%
Shares Short1.60M
Short (prev mo.)1.60M
Technical
SMA 505.208 (+35.7%)
SMA 2005.014 (+41.0%)
Beta2.83
S&P 52W Chg18.16%
Avg Vol (30d)253.10K
Avg Vol (10d)367.18K
Technical Indicators
RSI (14)72.7
MACD0.5266
MACD Signal0.3751
MACD Hist.+0.1515
BB Upper7.463 USD
BB Middle5.667 USD
BB Lower3.871 USD
BB Width63.38%
ATR (14)0.4285 USD
Vol Ratio (20d)2.44x